Boston Scientific and ArthroCare in heart deal:
This article was originally published in Clinica
Executive Summary
Boston Scientific is to develop and market ArthroCare's Coblation technology for use in myocardial revascularisation - the treatment of heart disease in which radiofrequency energy is used to stimulate the formation of new blood vessels. Boston will have exclusive licensing rights to ArthroCare's intellectual property and will pay licensing fees on completion of clinical and regulatory milestones. Financial terms were not disclosed.